Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease
Status:
Completed
Trial end date:
2011-04-28
Target enrollment:
Participant gender:
Summary
Protocol 610 is enrolling subjects who successfully achieved clinical benefit (reduction in
Crohn's Disease Activity Index (CDAI) of at least 100 points) in Protocol 603. Protocol 610
is evaluating the length of initial effect of PROCHYMAL® adult human mesenchymal stem cells
and the ability of these cells to successfully re-induce clinical benefit.